Comparative Pharmacology
Head-to-head clinical analysis: DETROL LA versus OXYBUTYNIN CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL LA versus OXYBUTYNIN CHLORIDE.
DETROL LA vs OXYBUTYNIN CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tolterodine is a competitive muscarinic receptor antagonist. It blocks acetylcholine binding at muscarinic receptors (M1–M5), reducing detrusor muscle contraction and bladder pressure, thereby increasing bladder capacity and decreasing urinary frequency.
Oxybutynin chloride is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3), leading to relaxation of the detrusor muscle and reduction of urinary bladder contractions.
4 mg orally once daily; may be reduced to 2 mg once daily based on tolerability.
5 mg orally 2-3 times daily; maximum 5 mg 4 times daily. Extended-release: 5-10 mg orally once daily; maximum 30 mg/day. Transdermal: 3.9 mg/day patch applied every 3-4 days. Topical gel: 1 g (100 mg) applied once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for the extended-release formulation, allowing once-daily dosing.
Terminal elimination half-life: 12–13 hours in plasma; clinical effect may persist longer due to active metabolite (N-desethyloxybutynin, half-life ~12–13 hours).
Approximately 77% eliminated in urine (primarily as metabolites, <1% unchanged) and 17% in feces.
Primarily hepatic metabolism; <0.1% excreted unchanged in urine. Metabolites (e.g., N-desethyloxybutynin) excreted mainly renally. Fecal elimination <0.02%.
Category C
Category A/B
Anticholinergic
Anticholinergic